Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0263 • ACR Convergence 2020
Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus
Stephanie Florez-Pollack¹, Syed Rizvi², Benjamin Chong² and Linda Hynan², ¹University of Pennsylvania, PHILADELPHIA, PA, ²University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a photosensitive skin disorder that can occur with systemic lupus erythematosus. As CLE often fluctuates in disease activity, little…
Abstract Number: 0279 • ACR Convergence 2020
Pulmonary Involvement in a Single Center Cohort of Patients with Systemic Lupus Erythematosus
Naci Senkal¹, Esen Kiyan², Elif Kocasoy-Orhan³, Ali Demir⁴, Mehmet Aydogan⁵, Yasemin Yalcinkaya⁶, Ahmet Gul⁶, Murat Inanc⁷, Mahdume Lale Öcal⁶ and Bahar Artım-Esen⁶, ¹Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ²Department of Chest Disease, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ³Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ⁴Fulya Radiologic Imaging Center, İstanbul, Turkey, ⁵Department of Cardiology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ⁶Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ⁷Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Background/Purpose: The prevalence of SLE pulmonary involvement varies depending on several factors, including diagnostic methods. In this study, we sought to determine the frequency of…
Abstract Number: 0297 • ACR Convergence 2020
Towards a Glucocorticoid Exposure Signature in SLE: Effects of Type I Interferon
Melissa Northcott¹, Linden Gearing², Hieu Nim³, Champa Nataraja³, Sarah Jones¹ and Eric Morand⁴, ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia, ²Hudson Institute of Medical Research, Clayton, Victoria, Australia, ³Monash University, Clayton, Victoria, Australia, ⁴Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: Glucocorticoids (GC), utilised in SLE for their broad immunosuppressive actions, predominantly mediate these effects by interaction with the cytoplasmic GC receptor (GR) to modulate…
Abstract Number: 0462 • ACR Convergence 2020
Lupus-like Autoimmunity and Increased Interferon Response in Patients with STAT3-deficient Hyper-IgE Syndrome
Brian Dizon¹, Rishi Goel², Shuichiro Nakabo², Amanda Urban², Meryl Waldman², Lilian Howard², Dirk Darnell², Munir Buhaya², Sarfaraz Hasni³, Mariana Kaplan⁴, Alexandra Freeman² and Sarthak Gupta¹, ¹National Institutes of Health, BETHESDA, MD, ²National Institutes of Health, Bethesda, ³Lupus Clinical Trials Unit, NIAMS/NIH, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD
Background/Purpose: Autosomal dominant hyper-IgE syndrome (AD-HIES), also known as Job’s syndrome, is a rare primary immunodeficiency caused by dominant-negative loss-of-function (LOF) mutations in signal transducer…
Abstract Number: 0591 • ACR Convergence 2020
Intervention to Improve SLE Medication Adherence Using Surescripts Pharmacy Refill Data
Kai Sun¹, Jennifer Rogers², Rebecca Sadun³, Amanda Eudy³, Jayanth Doss³, Lisa Criscione-Schreiber⁴, Ann Cameron Barr⁵, Lena Eder⁶, Mithu Maheswaranathan³, Amy Corneli⁷, Hayden Bosworth¹ and Megan Clowse⁸, ¹Duke University Hospital, Durham, ²Duke University Hospital, Durham, DE, ³Duke University, Durham, NC, ⁴Division of Rheumatology and Clinical Immunology, Department of Medicine, Duke University Medical Center, Durham, NC, ⁵Duke University Hospital, Durham, NC, ⁶Duke University Hospital, Chapel Hill, NC, ⁷Duke University, Durham, ⁸Duke University, Chapel Hill, NC
Background/Purpose: Medication nonadherence is as high as 80% among SLE patients and leads to higher morbidity, mortality, and healthcare costs. Few studies have tested interventions…
Abstract Number: 0846 • ACR Convergence 2020
MHC Class I Epitopes Derived from Autoantibody Variable Regions, Conjugated to Synthetic Oligodeoxynuleotides, Induce Cytotoxic T Cells That Deplete Autoreactive B Cells and Ameliorate Murine Lupus
Ram Singh¹, ¹UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: B cell depletion or modulation is emerging as a major treatment modality for autoimmune diseases. However, the current treatments to accomplish this non-specifically target…
Abstract Number: 0864 • ACR Convergence 2020
Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression in Patients with Systemic Lupus Erythematosus
Lisa Zhu¹, Manpreet Singh², Caroline Siegel³, Lori Sahakian², Jennifer Grossman⁴ and Maureen McMahon⁵, ¹University of California, Los Angeles, Van Nuys, CA, ²University of California, Los Angeles, Los Angeles, CA, ³Hospital for Special Surgery, New York, NY, ⁴University of California, Los Angeles, Sherman Oaks, CA, ⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: Hydroxychloroquine (HCQ) has demonstrated a wide array of beneficial effects in patients with systemic lupus erythematosus (SLE), with regard to disease activity, flare rates,…
Abstract Number: 0981 • ACR Convergence 2020
Mortality Among Minority Populations with Systemic Lupus Erythematosus, Including Asian and Hispanic Status: The California Lupus Surveillance Project, 2007-2017
Milena Gianfrancesco¹, Maria Dall'Era², Louise Murphy³, Charles Helmick³, Jing Li¹, Stephanie Rush¹, Laura Trupin¹ and Jinoos Yazdany⁴, ¹University of California, San Francisco, San Francisco, CA, ²Division of Rheumatology, University of California, San Francisco, CA, ³Centers for Disease Control and Prevention, Atlanta, GA, ⁴UCSF, San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease with manifestations that vary widely in severity. Contemporary data indicate that minority populations are at…
Abstract Number: 1024 • ACR Convergence 2020
Time Trends in the Incidence of Systemic Lupus Erythematosus: A 40-Year Study
Ali Duarte-Garcia¹, Mehmet Hocaoglu², Shirley-Ann Osei-Onomah³, Jesse Dabit¹, Rachel Giblon¹ and Cynthia Crowson⁴, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Changes over time in the incidence of Systemic Lupus Erythematosus (SLE) remain uncertain. It is unclear if the variations in established SLE risk factors,…
Abstract Number: 1262 • ACR Convergence 2020
Single LAC Positivity versus Double and Triple Positivity for Thrombosis in SLE
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose:Antiphospholipid syndrome (APS) is classified as the development of venous and/or arterial thromboses, and pregnancy morbidity, in the presence of antiphospholipid antibodies (aPL); lupus anticoagulant,…
Abstract Number: 1278 • ACR Convergence 2020
Does Co-existing Systemic Lupus Erythematosus Affect Outcomes of Hospitalizations for Ischemic Stroke?
Ehizogie Edigin¹, Precious Eseaton², Pius Ojemolon³ and Augustine Manadan⁴, ¹John H Stroger Jr. Hospital of Cook County, Chicago, IL, ²University of Benin Teaching Hospital, Benin, ³St. George's University, St. George's, Grenada, ⁴Cook County Hospital/Rush University Medical center, Chicago, IL
Background/Purpose: Various studies have shown that individuals with Systemic Lupus Erythematosus (SLE) have a higher risk of stroke and cerebrovascular events than the general population. These events represent a significant…
Abstract Number: 1294 • ACR Convergence 2020
Prediction of Damage in SLE Using Unbiased Analysis of Large Datasets
Eric Morand¹, Dinith Liyanage², Rita Hoang², Vera Golder², Worawit Louthrenoo³, Shue Fen Luo⁴, Yeong-Jian Wu⁵, Sargunan Sockalingam⁶, Susan Morton⁷, Sandra Navarra⁸, Leonid Zamora⁹, Laniyati Hamijoyo¹⁰, Yasuhiro Katsumata¹¹, Masayoshi Harigai¹², Madelynn Chan¹³, Sean O'Neill¹⁴, Fiona Goldblatt¹⁵, Chak Sing Lau¹⁶, Zhanguo Li¹⁷, Julie Bonin², Rachel Koelmeyer², Mandana Nikpour¹⁸, Rangi Kandane-Rathnayake² and Hieu Nim², ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²Monash University, Clayton, Victoria, Australia, ³Chiang Mai University Hospital, Muang, Thailand, ⁴Chang Gung Memorial Hospital-Linkou, Taoyuan, Taipei, Taiwan (Republic of China), ⁵Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), ⁶University of Malaya, Kuala Lumpur, Malaysia, ⁷Monash Health, Clayton, Victoria, Australia, ⁸University of Santo Tomas, Manila, Philippines, ⁹University of Santo Thomas, Manila, Philippines, ¹⁰University of Padjadjaran, Bandung, Indonesia, ¹¹Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ¹³Tan Tock Seng Hospital, Singapore, Singapore, ¹⁴Sydney University, Sydney, Australia, ¹⁵Royal Adelaide Hospital, Adelaide, Australia, ¹⁶Hong Kong University, Hong Kong, Hong Kong, ¹⁷Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic), ¹⁸The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia
Background/Purpose: A key goal of treatment of SLE is the prevention of irreversible organ damage. The ability to identify patients at increased risk for damage…
Abstract Number: 1475 • ACR Convergence 2020
Predictors of Thirty-Day Hospital Readmissions in Systemic Lupus Erythematosus in the US: A Nationwide Study
Rayan Najjar¹, Swetha Ann Alexander², Grant Hughes¹, Jinoos Yazdany³ and Namrata Singh⁴, ¹University of Washington, Seattle, WA, ²University of Connecticut, Hartford, CT, ³UCSF, San Francisco, CA, ⁴University of Washington, Bellevue, WA
Background/Purpose: For individuals with systemic lupus erythematosus (SLE), hospital readmission rate is associated with quality of care and prognosis. Our objective was to evaluate independent…
Abstract Number: 1616 • ACR Convergence 2020
Systematic Review of Effectiveness Outcomes Reported in Rheumatology Transition Literature
Heather Bannerman¹, Karen Beattie¹, Avanti Patel², Milica Tanic², Michelle Batthish³ and Mark Matsos², ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: In young patients with rheumatologic disease, transition from pediatric to adult care is a complex process. Poor transitional care leads to health deterioration, loss…
Abstract Number: 1679 • ACR Convergence 2020
Developing a Standardized Corticosteroid Dosing Regimen in Pediatric Proliferative Lupus Nephritis
Nathalie Chalhoub¹, Kelly Rouster-Stevens², Marisa Klein-Gitelman³, Karen Onel⁴, Beatrice Goilav⁵, Sonia Savani⁶, Natasha Ruth⁶, Tingting Qiu⁷, Najla Aljaberi⁸, Jianghong Deng⁹, Angela Merritt⁸, Benjamin Laskin¹⁰, Anna Carmela Sagcal-Gironella¹¹, Stacy Ardoin¹², Deborah Levy¹³, Scott Wenderfer¹⁴, Bin Huang⁷, Hermine I Brunner¹⁵ and LaUNCH Project Investigators¹⁶, ¹The University of Cincinnati College of Medicine, Cincinnati, OH, ²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁴Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁵The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁶Medical University of South Carolina, Charleston, SC, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Beijing Children’s Hospital, Beijing, China (People's Republic), ¹⁰Children's Hospital of Philadelphia, Philadelphia, ¹¹Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ, ¹²Nationwide Children's Hospital, Columbus, OH, ¹³Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁴Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, ¹⁵PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁶LUpus Nephritis and Cellcept precision dosing in cHildren (LaUNCH), Cincinnati, OH
Background/Purpose: Corticosteroids (CS) remain the mainstay of therapy for childhood-onset systemic lupus erythematosus (cSLE). However, widely accepted strategies for oral (PO) or intravenous (IV) CS…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].